Almost 70 product-specific guidances have been published by the US Food and Drug Administration at the start of June, with the 69 guidances published comprising 26 new PSGs and 43 revised documents.
Among the new PSGs are documents covering subcutaneous extended-release buprenorphine, estradiol extended-release vaginal inserts and fluorometholone ophthalmic suspension. They...




